Workflow
肺动脉取栓支架系统
icon
Search documents
南通长江体育公园足球片区月底开放 | 南通早七点
Sou Hu Cai Jing· 2025-08-26 22:40
Group 1 - China's largest offshore floating liquefied natural gas facility, NGUYA (恩古雅) FLNG, has been launched in Nantong, marking a significant advancement in the country's energy infrastructure [3] - The facility is designed to have the largest tonnage and storage capacity, indicating a strong commitment to enhancing natural gas supply capabilities [3] - Key figures from the event included local government officials and representatives from international energy companies, highlighting collaboration in the energy sector [3] Group 2 - Nantong's economy has shown resilience and potential, with steady growth in major sectors such as industry, services, and foreign trade [5] - The local government plans to continue reinforcing the economic recovery and leverage policy effects to promote further development [5] - The construction of the Jiangsu Changjiang Sports Park, a key ecological project, is set to enhance recreational spaces for residents, reflecting a focus on sustainable urban development [6] Group 3 - Two innovative medical devices have received approval from the National Medical Products Administration, showcasing advancements in the healthcare sector [6] - The approved devices include a cerebral aneurysm embolization stent and a pulmonary artery thrombectomy stent system, indicating growth in the medical technology industry [6] Group 4 - The upcoming 2025 Haimen Marathon will creatively incorporate the local textile industry, introducing a DIY textile bib number for participants, which may enhance community engagement and promote local culture [6][7] - The opening of two new high-standard school campuses in Chongchuan District is expected to improve educational resources and infrastructure, contributing to the region's educational development [7]
江苏省2款第三类创新医疗器械获批上市
Yang Zi Wan Bao Wang· 2025-08-26 10:18
Group 1 - Jiangsu Changyida Medical Technology Co., Ltd. and Morningstar (Nantong) Medical Device Co., Ltd. have received approval from the National Medical Products Administration for their innovative Class III medical devices, namely the "Intracranial Aneurysm Assisting Embolization Stent" and the "Pulmonary Artery Thrombectomy Stent System" respectively [1][2] - In 2023, a total of 9 innovative Class III medical devices have been approved for market entry in Jiangsu Province [1] - The "Intracranial Aneurysm Assisting Embolization Stent" features a self-expanding elastic structure with adjustable length and flared ends, aimed at reducing vascular damage and enhancing vascular adhesion [1] Group 2 - The "Pulmonary Artery Thrombectomy Stent System" is designed for mechanical thrombectomy via the femoral vein, utilizing a large-caliber thrombus suction catheter to quickly restore blood flow [2] - This device offers a short preoperative preparation time, high efficiency in thrombus removal during the procedure, and rapid postoperative recovery [2] - The stent system includes various models with a gradient design for the mesh disk, which is intended to be more compatible with target blood vessels and reduce the risk of vascular damage [2] Group 3 - The Jiangsu Provincial Drug Administration is focusing on core technology breakthroughs and addressing "bottleneck" technologies to promote innovative medical device development [3] - The administration aims to enhance the transformation of clinical research results into practical applications, fostering collaboration between medical and industrial sectors [3] - Efforts are being made to reform the review and approval system, optimize the industrial ecosystem, and increase the international competitiveness of high-end medical devices in Jiangsu Province [3]
数千万元!玄宇医疗连续完成两轮融资
思宇MedTech· 2025-04-02 10:06
合作伙伴征集:2025全球手术机器人大会 近日, 上海玄宇医疗器械有限公司 (以下简称"玄宇医疗")宣布连续完成由 倚锋灼华 投资的 数千万元A++轮融资 和 白云金控 投资 的 数千万元A+++轮融 资 。 本 轮融资将重点投向营销网络建设、产业化基地扩建及创新研发管线布局,通过 "技术+市场"双轮驱动 巩固行业领先地位。 此次融资将助力 玄宇医 疗 以临床价值为导向,采取 '精准研发+精益生产+精细运营'的模式 ,通过DFSS+DFM的设计理念驱动,进行满足临床需求的差异化产品设计和多产品差异 化矩阵布局。 # 产品与技术 其核心产品 RHYTHPULSE ® 多通道脉冲电场消融(PFA)系统 已于今年2月26日正式 通过NMPA批准上市 ,成为 国产首个获批的集多通道、大局灶和靶向消融 于一体的PFA系统 , 标志着我 国心脏电生理领域正式进入精准消融新时代 。公司核心产品包括: 报名:首届全球眼科大会 | 议程更新 报名:首届全球心血管大会 | 奖项申报 报名:首届全球骨科大会 | 奖项评选 多通道心脏脉冲电场消融系统 :由 SHINERHYTHM ® 多通道心脏脉冲电场消融仪与RHYTHPULSE ...